Study guide

3.2 Heart Failure and Cardiac Disease Progression

Certified Hospice and Palliative Nurse CHPN

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 Current Exam Facts 1.2 Eligibility, Fees, Windows, and Retakes 1.3 Scoring, Test-Day Rules, and Remote Proctoring 1.4 Recertification: HPAR and the Situational Judgment Exercise

2 Chapter 2: Assessment, Goals, and Care Planning

2.1 Goals of Care and Shared Decision Making 2.2 Interdisciplinary Care Planning and Ongoing Evaluation 2.3 Prognostic and Functional Assessment Tools 2.4 Levels of Care and Care-Setting Transitions

3 Chapter 3: Life-Limiting Disease Progression I

3.1 Cancer, Hematologic, and Paraneoplastic Complications 3.2 Heart Failure and Cardiac Disease Progression 3.3 Pulmonary Disease Progression 3.4 Neurologic Disease Progression

4 Chapter 4: Disease Progression II and Imminent Death

4.1 Dementia, Frailty, and Feeding Decisions 4.2 Renal, Hepatic, and Endocrine Trajectories 4.3 Indicators of Imminent Death

5 Chapter 5: Pain Assessment

5.1 Pain Types, Etiology, and Syndromes 5.2 Verbal and Nonverbal Pain Assessment and Scales 5.3 Factors That Influence the Pain Experience

6 Chapter 6: Pharmacologic Pain Management

6.1 Opioid and Non-Opioid Analgesics by Pain Type and Severity 6.2 Adjuvant Analgesics 6.3 Titration, Baseline Dosing, and Breakthrough Pain 6.4 Equianalgesic Conversion and Route Changes

7 Chapter 7: Nonpharmacologic Pain and Opioid Safety

7.1 Nonpharmacologic Pain Interventions 7.2 Complementary and Integrative Pain Therapies 7.3 Opioid Adverse Effects, Neurotoxicity, and Rotation

8 Chapter 8: Neurological, Cardiovascular, and Respiratory Symptoms

8.1 Neurological Symptoms 8.2 Delirium and Terminal Restlessness 8.3 Cardiovascular Symptoms 8.4 Respiratory Symptoms: Dyspnea, Cough, and Secretions

9 Chapter 9: Gastrointestinal, Genitourinary, and Musculoskeletal Symptoms

9.1 Gastrointestinal Symptoms 9.2 Genitourinary Symptoms 9.3 Musculoskeletal Symptoms

10 Chapter 10: Skin, Metabolic, Hematologic, and Psychospiritual Symptoms

10.1 Skin and Mucous Membrane Symptoms 10.2 Nutritional and Metabolic Symptoms 10.3 Immune and Hematologic Symptoms 10.4 Psychosocial, Emotional, and Spiritual Symptom Burden

11 Chapter 11: Advance Care Planning, Benefits, and Safety

11.1 Advance Care Planning and Life-Sustaining Therapies 11.2 Hospice and Palliative Benefits under Medicare, Medicaid, and Private Insurance 11.3 Patient Safety: Environmental, Physical, and Socioemotional

12 Chapter 12: Communication, Culture, and Psychosocial Support

12.1 Communication Techniques, Barriers, and Family Meetings 12.2 Cultural Humility and Spiritual Needs 12.3 Psychosocial Needs and IDG Participation

13 Chapter 13: Caregiver Education and Medication Management

13.1 Medication Management and Controlled Substances 13.2 Caregiver and Family Self-Care 13.3 Teaching End-Stage Disease, Pain, and Symptom Plans 13.4 Caregiver Skills, DME, Supplies, and Services

14 Chapter 14: Grief, Death, and End-of-Life Ethics

14.1 Grief, Loss, and Bereavement 14.2 Support at the Time of Death and Post-Mortem Care 14.3 Ethical Issues Related to End of Life

15 Chapter 15: Medicare Hospice Compliance and National Standards

15.1 Medicare Hospice Benefit and Conditions of Participation 15.2 Hospice Eligibility, Admission, and Recertification 15.3 National Hospice and Palliative Care Standards 15.4 National Consensus Project Clinical Practice Guidelines

16 Chapter 16: Legal, Professional Practice, Quality, and Policy

16.1 Legal Regulations: CMS, HIPAA, and OSHA 16.2 Professional Boundaries and Ethics 16.3 QAPI, Self-Care, and Precepting 16.4 Policy, Delivery, and Reimbursement Trends

3.2 Heart Failure and Cardiac Disease Progression

Key Takeaways Explain This Topic AI

Heart failure with reduced ejection fraction and heart failure with preserved ejection fraction can both reach NYHA class III–IV hospice-eligible decline; recurrent hospitalizations are a stronger decline signal than a single ejection-fraction number.

ICD shock therapies at the end of life are distressing; deactivating tachyarrhythmia therapies after an informed conversation is not euthanasia. The CHPN RN coordinates the plan and does not reprogram or implant devices.

Continuous milrinone or dobutamine can palliate rest dyspnea in selected programs, but hospice election may not cover home inotropes; destination LVAD care is a coordinated deactivation conversation with the VAD team, not a bedside RN implant or explant.

Diuretic resistance, hyponatremia, and cardiorenal worsening mark advancing disease. Treat ischemic chest pain as angina when that is the symptom; do not confuse it with air hunger of active dying.

Last updated: August 2026

Cardiac decline on a 150-item RN board

Heart failure is one of the most common non-cancer hospice diagnoses, and it is a favorite CHPN trap because the patient can look “stable” between crises. Domain 1.C wants the pattern: New York Heart Association (NYHA) class III–IV limitation, stacked hospitalizations, shrinking response to diuretics, and a device or infusion that now collides with dying. The CHPN RN coordinates ; you do not implant defibrillators, left ventricular assist devices, or inotrope catheters.

HFrEF versus HFpEF, and why NYHA still matters

Heart failure with reduced ejection fraction (HFrEF) is a left-ventricular ejection fraction of 40% or less —a squeezing problem. Heart failure with preserved ejection fraction (HFpEF) is typically 50% or greater —a filling problem, more often in older adults with hypertension, diabetes, obesity, and atrial fibrillation. Exam writers love the false rule that only a low ejection fraction qualifies for hospice. A patient with HFpEF, anasarca, and dyspnea at rest can be as hospice-eligible as a patient with an ejection fraction of 15%.

NYHA class III means marked limitation: ordinary activity (dressing, walking across a room) causes symptoms, but the patient is comfortable at rest. NYHA class IV means symptoms at rest. Hospice conversations cluster in III–IV, especially when guideline-directed therapy is already maximized or no longer tolerated. Do not wait for a single magic ejection-fraction cutoff. Recurrent hospitalizations—two or more unplanned stays in six months for congestion, arrhythmia, or kidney injury—are often the decline signal families recognize before they accept the word hospice.

  • Feature HFrEF HFpEF
  • Typical EF 40% or less About 50% or greater
  • Dominant mechanics Impaired squeeze Impaired fill / stiff ventricle
  • Common companions Prior infarct, dilated cardiomyopathy Aging, hypertension, diabetes, obesity
  • NYHA III–IV possible? Yes Yes
  • Hospice if EF is “normal”? N/A Yes, if function and crises match advanced disease
  • Destination LVAD Selected advanced HFrEF Not a standard HFpEF therapy
  • Inotropes, hospice election, and home infusions

Intravenous dobutamine or milrinone can reduce rest dyspnea and congestion when the pump can no longer respond to oral therapy. That is palliation, not a cure. It is also disease-modifying support : many hospice programs cannot pay for continuous home inotropes under the Medicare hospice benefit, some partner with an advanced-heart-failure clinic in an “open-access” model, and some will continue a time-limited infusion while the goal is comfort at home. There is no single national switch that says every inotrope must stop the morning hospice is elected. The CHPN RN names the implication: electing hospice may mean the infusion vendor, the pump, and the laboratory monitoring are no longer funded the same way. Coordinate with the hospice medical director and the heart-failure team before the family is surprised by a stopped drip.

Home milrinone or dobutamine exists in selected programs with infusion nursing, implantable or midline access, and a plan for hypotension, arrhythmia, and line infection. The CHPN RN does not independently start the drug, place the line as a certified implanter, or promise that every hospice will honor the drip.

ICD shocks, pacemakers, and LVAD complexity

An implantable cardioverter-defibrillator (ICD) can deliver painful shocks while a patient is actively dying from pump failure or respiratory collapse. Those shocks do not restore a meaningful life; they terrorize the room. Deactivating tachyarrhythmia therapies after an informed conversation with the patient or legal decision-maker is not euthanasia . The device simply stops shocking. Bradycardia pacing, if present in a dual-function device, is a separate decision; many teams leave pacing on because abrupt pacemaker-dependent collapse can increase dyspnea. A magnet may temporarily inhibit shocks in a crisis; lasting deactivation is a reprogramming visit by electrophysiology or another privileged clinician. The CHPN RN raises the topic early, documents the goal, and coordinates the visit. You do not reprogram the generator yourself.

A left ventricular assist device (LVAD) as destination therapy (not as a bridge to transplant) creates a hospice problem set: driveline infection, anticoagulation, battery and controller teaching, and the meaning of turning the pump off . Deactivating an LVAD usually leads to death within minutes to hours from loss of forward flow. That conversation belongs with the VAD team, the hospice medical director, and the family—never as a surprise bedside experiment. Bridge-to-transplant patients who elect hospice have usually already left the transplant pathway; still, coordinate rather than assume. The CHPN RN does not implant, explant, or “turn off” a pump without that team structure.

Diuretic resistance, hyponatremia, cardiorenal decline, angina versus dying

Diuretic resistance is congestion that no longer yields to escalating loop diuretics, even with thiazide add-on, inotropes, or sequential blockade. Hyponatremia in advancing heart failure is a prognostic warning, not just a sodium number to chase with hypertonic saline on hospice. Cardiorenal syndrome is the loop in which worse congestion injures the kidney and worse kidney function blocks diuresis. Creatinine creep plus oliguria plus rest dyspnea is a trajectory, not a one-time lab error.

Angina is ischemic chest pain; treat it as pain (nitrates, opioids, oxygen if hypoxemic, rest). Dying from heart failure is often air hunger, Cheyne–Stokes breathing, cool mottled skin, and fading pulse—not a textbook pressure-like angina. The CHPN RN still treats chest pain if it is present, and still treats dyspnea if that is the dominant distress. Do not withhold opioids for air hunger because “this is a heart patient.” Opioid titration for dyspnea is taught later; the assessment point here is to name the symptom correctly so the plan matches the dying physiology rather than an old catheterization report.

Loading diagram... ICD shock-therapy deactivation is coordination, not RN reprogramming